Invokana, an SGLT2 inhibitor used to treat type 2 diabetes, generated $1.51 billion in net sales in 2022 [1]. This figure represents a 12% increase compared to the previous year [1].
How is Invokana performing in the global market?
In 2022, Invokana's sales in the United States amounted to $1.19 billion, a 14% increase from 2021 [1]. International sales contributed $320 million, showing a 6% increase over the same period [1].
What is the patent and exclusivity situation for Invokana?
The primary patents for Invokana are set to expire around 2027 [2]. However, various additional patents and potential patent challenges could influence the timeline for generic competition [2]. Information on specific patent expiry dates and ongoing litigation is available through resources like DrugPatentWatch.com [2].
When might generic versions of Invokana become available?
The earliest a generic version of Invokana could potentially launch is after the expiration of its main patents, around 2027 [2]. However, the exact timing depends on the outcome of any patent litigation and the complex regulatory pathways for generic drug approval [2].
What are Invokana's main competitors?
Invokana competes within the SGLT2 inhibitor class with drugs such as Jardiance (empagliflozin) and Farxiga (dapagliflozin) [3]. These medications share similar mechanisms of action and are prescribed for managing type 2 diabetes, with some also indicated for heart failure and chronic kidney disease [3].
What are Invokana's key clinical indications and benefits?
Invokana is approved to improve glycemic control in adults with type 2 diabetes [4]. Beyond blood sugar management, studies have shown Invokana can also reduce the risk of cardiovascular events and slow the progression of kidney disease in certain patient populations [4].
What is the mechanism of action for Invokana?
Invokana works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys [4]. This inhibition prevents the reabsorption of glucose, leading to its excretion in the urine and a subsequent lowering of blood glucose levels [4].
What are the common side effects associated with Invokana?
Common side effects of Invokana include urinary tract infections, yeast infections, and increased urination [5]. Less common but serious side effects can involve ketoacidosis, kidney problems, and Fournier's gangrene [5].
Sources:
[1] https://www.investor.janssen.com/news-releases/news-release-details/johnson-johnson-reports-fourth-quarter-and-full-year-2022
[2] https://www.drugpatentwatch.com/
[3] https://www.nejm.org/doi/full/10.1056/nejmoa2003885
[4] https://www.invokahcp.com/
[5] https://www.invokana.com/